Log in

LON:MPHMereo BioPharma Group Share Price, Forecast & News

GBX 46.50
-0.50 (-1.06 %)
(As of 07/10/2020 04:00 PM ET)
Today's Range
Now: GBX 46.50
50-Day Range
MA: GBX 37.29
52-Week Range
Now: GBX 46.50
Volume23,315 shs
Average Volume266 shs
Market Capitalization£157.50 million
P/E RatioN/A
Dividend YieldN/A
Mereo BioPharma Group plc, a specialty biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of rare and specialty diseases. Its product candidates include BPS-804, a monoclonal antibody, which is in Phase IIb clinical trial for the treatment of osteogenesis imperfecta; AZD-9668, an oral small molecule that has been completed Phase I clinical trial to treat Alpha-1 antitrypsin deficiency; BGS-649, an oral aromatase inhibitor, which is in Phase IIb clinical trial for the treatment of hypogonadal hypogonadism; and BCT-197, an oral p38 MAP kinase inhibitor that is in Phase II clinical trial to treat acute exacerbations of chronic obstructive pulmonary disease. Mereo BioPharma Group plc was founded in 2015 and is headquartered in London, the United Kingdom.
Read More
Mereo BioPharma Group logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.56 out of 5 stars

Industry, Sector and Symbol

Industry Biotechnology
Phone44 33 3023 7300



Sales & Book Value

Annual SalesN/A
Cash FlowGBX 7.38 per share
Book ValueGBX 41.10 per share



Market Cap£157.50 million
Next Earnings DateN/A
OptionableNot Optionable

Receive MPH News and Ratings via Email

Sign-up to receive the latest news and ratings for MPH and its competitors with MarketBeat's FREE daily newsletter.

Mereo BioPharma Group (LON:MPH) Frequently Asked Questions

How has Mereo BioPharma Group's stock been impacted by COVID-19 (Coronavirus)?

Mereo BioPharma Group's stock was trading at GBX 25.50 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MPH shares have increased by 82.4% and is now trading at GBX 46.50. View which stocks have been most impacted by Coronavirus.

How were Mereo BioPharma Group's earnings last quarter?

Mereo BioPharma Group PLC (LON:MPH) announced its quarterly earnings results on Tuesday, June, 16th. The company reported ($39.00) earnings per share for the quarter, missing the consensus estimate of ($27.50) by $11.50. View Mereo BioPharma Group's earnings history.

Has Mereo BioPharma Group been receiving favorable news coverage?

Media headlines about MPH stock have been trending neutral recently, InfoTrie reports. The research firm ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Mereo BioPharma Group earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news about Mereo BioPharma Group.

Who are some of Mereo BioPharma Group's key competitors?

What other stocks do shareholders of Mereo BioPharma Group own?

Who are Mereo BioPharma Group's key executives?

Mereo BioPharma Group's management team includes the following people:
  • Dr. Denise Scots-Knight, Co-Founder, Chief Exec. Officer & Exec. Director (Age 60)
  • Mr. Richard Crispin Morgan Jones, CFO & Exec. Director (Age 53)
  • Mr. Charles Sermon, Co-Founder, Gen. Counsel & Company Sec. (Age 50)
  • Dr. Alastair MacKinnon, Co-Founder & Chief Medical Officer (Age 49)
  • Mr. John Richard, Co-Founder & Head of Corp. Devel. (Age 62)

What is Mereo BioPharma Group's stock symbol?

Mereo BioPharma Group trades on the London Stock Exchange (LON) under the ticker symbol "MPH."

How do I buy shares of Mereo BioPharma Group?

Shares of MPH and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Mereo BioPharma Group's stock price today?

One share of MPH stock can currently be purchased for approximately GBX 46.50.

How big of a company is Mereo BioPharma Group?

Mereo BioPharma Group has a market capitalization of £157.50 million. Mereo BioPharma Group employs 31 workers across the globe.

What is Mereo BioPharma Group's official website?

The official website for Mereo BioPharma Group is mereobiopharma.com.

How can I contact Mereo BioPharma Group?

Mereo BioPharma Group's mailing address is 1 Cavendish Place, LONDON, W1G 0QF, United Kingdom. The company can be reached via phone at 44 33 3023 7300.

This page was last updated on 7/11/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.